[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.184.210. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
February 9, 2011

KRAS Genotypes and Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

JAMA. 2011;305(6):564-566. doi:10.1001/jama.2011.86

To the Editor: Dr De Roock and colleagues1 studied the effect of KRAS p.G13D mutation on cetuximab efficacy in chemotherapy-refractory metastatic colorectal cancer. The authors concluded that patients with KRAS p.G13D-mutated tumors have longer overall survival and progression-free survival than patients with other KRAS -mutated tumors.

First Page Preview View Large
First page PDF preview
First page PDF preview
×